Related Experiment Video
Updated: Feb 28, 2026
06:21
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
11.1K
[Lipid metabolism in patients with hematologic cancers]
S G Vladimirova1, L N Tarasova1
1Kirov Research Institute of Hematology and Blood Transfusion, Federal Biomedical Agency of Russia, Kirov, Russia.
Terapevticheskii Arkhiv
|June 22, 2017
Summary
Low cholesterol levels in patients with hematologic cancers indicate increased cancer cell demand. Cholesterol, its fractions, and apolipoproteins can serve as prognostic markers for these cancers.
Area of Science:
- Oncology
- Biochemistry
- Lipid Metabolism
Background:
- High cholesterol (hypercholesterolemia) is typically viewed as detrimental.
- However, cholesterol is vital for cell proliferation, and low levels may indicate increased demand by neoplastic cells.
- This review examines lipid metabolism in hematologic cancer patients.
Purpose of the Study:
- To review current literature on lipid metabolism alterations in hematologic cancers.
- To explore the role of cholesterol and related molecules as prognostic markers.
- To consider the impact of chemotherapy on lipid metabolism and potential new treatment strategies.
Main Methods:
- Literature review of recent investigations.
- Analysis of serum lipid profiles in hematologic cancer patients at various disease stages.
- Examination of cholesterol synthesis, absorption, and release mechanisms in cancer cells.
Main Results:
- Significant reduction in total cholesterol and high-density lipoproteins observed at the onset of hematologic diseases.
- Cholesterol accumulation in leukemia cells due to enhanced synthesis, absorption, and blocked release.
- Lipid parameters normalize with favorable disease course/remission and decline with progression.
Conclusions:
- Cholesterol, its fractions, and apolipoproteins show potential as biochemical prognostic markers in hematologic cancers.
- These markers can also assess treatment efficacy.
- Chemotherapeutic agents impact lipid metabolism, suggesting new therapeutic avenues targeting lipid pathways.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:01Regulation of Hematopoietic Stem Cells
4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
250
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250
01:28Role of Hematopoietic Growth Factors
4.1K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
4.1K
01:24Overview of Lipid Metabolism
6.1K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.1K